Table 4 Prognostic factors in patients underrepresented in large studies (minimum number of patients n = 20)
From: Prognostic indices for brain metastases – usefulness and challenges
Author | Population | Significant prognostic factors |
|---|---|---|
Ogawa et al.60 | esophageal cancer, n = 36 | KPS, aggressive local treatment (multivariate) |
Weinberg et al.61 | esophageal cancer, n = 27 | no liver metastases, RPA class I (trend, p = 0.1, multivariate) |
Khuntia et al.62 | esophageal cancer, n = 27 | KPS, aggressive local treatment (multivariate) |
Cohen et al.63 | ovarian cancer, n = 72 | aggressive local treatment |
Cormio et al.64 | ovarian cancer, n = 22 | extracranial disease, time to development of brain metastases |
Growdon et al.65 | gynaecological cancers, n = 30 | extracranial disease, histology, use of chemotherapy (multivariate) |
Tremont-Lukats et al.66 | prostate cancer, n = 103 | adenocarcinoma vs other histology |
Rades et al.24 | unknown primary, n = 101 | KPS, extracranial metastases, RPA class |
Bartelt and Lutterbach67 | unknown primary, n = 47 | KPS, surgical resection status (multivariate) |
Ruda et al.68 | unknown primary, n = 33 | number of brain metastases (multivariate) |
Kim et al.69 | patients ≥ 75 years, SRS treatment, n = 44 | single brain metastasis, NSCLC vs other primary |
Noel et al.70 | patients ≥ 65 years, SRS treatment, n = 117 | KPS (multivariate) |